Praliciguat (Standard)
Praliciguat (Standard) is the analytical standard of Praliciguat (HY-109039). This product is intended for research and analytical applications. Praliciguat (IW-1973) is a potent and orally active soluble guanylate cyclase (sGC) activator. Praliciguat can increases cGMP via the nitric oxide (NO)-sGC pathway. Praliciguat can inhibit the expression of proinflammatory cytoKines and inhibit apoptosis. Praliciguat can promote vasodilation. Praliciguat can be used for the researches of metabolic disease and cardiovascular disease, such as hypertension, diabetes and heart failure.
For research use only. We do not sell to patients.
- CAS No.: 1628730-49-3
- Formula: C21H14F8N6O2
- Molecular Weight:534.36
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Product Information
The compound is the grade of analytical standard, which is the reference standard supplied assay. It is commonly used in qualitative, quantitative and methodological research experiments in HPLC, GC and MS.
Chemical Information
-
CAS No. 1628730-49-3
-
Molecular Weight 534.36
-
Formula C21H14F8N6O2
-
SMILES
FC1=C(C=CC=C1)CN2C(C3=NOC=C3)=CC(C4=NC=C(F)C(NCC(C(F)(F)F)(O)C(F)(F)F)=N4)=N2
-
Synonyms
IW-1973 (Standard)
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
[2]. Liu G, et al. Praliciguat inhibits progression of diabetic nephropathy in ZSF1 rats and suppresses inflammation and apoptosis in human renal proximal tubular cells. Am J Physiol Renal Physiol. 2020 Oct 1;319(4):F697-F711. [Content Brief]
[3]. Shea CM, et al. Soluble guanylate cyclase stimulator praliciguat attenuates inflammation, fibrosis, and end-organ damage in the Dahl model of cardiorenal failure. Am J Physiol Renal Physiol. 2020 Jan 1;318(1):F148-F159. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)